Literature DB >> 3217919

A simple method to measure dermatan sulfate at sub-microgram concentrations in plasma.

D Dupouy1, P Sié, F Dol, B Boneu.   

Abstract

A simple method for biological assay of dermatan sulfate (DS) in plasma is described. DS accelerates thrombin inhibition by heparin cofactor II (HC II). The principle of the assay is to measure the residual amidolytic thrombin activity after a short period of incubation with HC II in defibrinated plasma at low ionic strength. For this method we take advantage of two observations. Firstly, at fixed concentrations of DS and of HC II, the rate of thrombin inhibition increases when the ionic strength of the medium decreases. Secondly, defibrination by bentonite absorption also removes antithrombin III, HC II and for a large part alpha-2 macroglobulin from the plasma, so that no other thrombin inhibitor competes with HC II added as a reagent in a second step. In the conditions described, there is a linear relationship between DS concentrations in plasma from 0 to 2 micrograms/ml and the log of residual thrombin activity. The limit of sensitivity is 0.1 micrograms/ml. The assay displays an acceptable reproducibility in intra-assay, inter-assay and inter-individual experiments. It can be used to measure DS in human, rabbit and rat plasmas. The assay is also sensitive to other HC II activators such as heparin and pentosan polysulfate. DS is effective in experimental thrombosis without any detectable anticoagulant effect ex vivo. Pharmacological concentrations of DS in plasma fall into the range of sensitivity of this assay, which would be helpful in experimental or clinical studies of DS and related glycosaminoglycans.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3217919

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  The pharmacokinetics of dermatan sulphate MF701 in healthy human volunteers.

Authors:  J Dawes; M McLaren; C Forbes; J J Belch; D A Lane; B Bray; J McEwen; G Houin; F Gianese
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

2.  An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus.

Authors:  M Andrew; L Mitchell; L Berry; B Paes; M Delorme; F Ofosu; R Burrows; B Khambalia
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

3.  The pharmacokinetics and pharmacodynamics of dermatan sulphate MF701 during haemodialysis for chronic renal failure.

Authors:  F Gianese; M T Nurmohamed; B P Imbimbo; H R Büller; R J Berckmans; J W Ten Cate
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

4.  Structure and contribution to the heparin cofactor II-mediated inhibition of thrombin of naturally oversulphated sequences of dermatan sulphate.

Authors:  G Mascellani; L Liverani; P Bianchini; B Parma; G Torri; A Bisio; M Guerrini; B Casu
Journal:  Biochem J       Date:  1993-12-15       Impact factor: 3.857

5.  Pharmacokinetics and pharmacodynamics of intramuscular dermatan sulfate revisited : a single- and repeated-dose study in healthy volunteers.

Authors:  Sylvie Saivin; Jean-Pierre Cambus; Claire Thalamas; Geneviève Lau; Bernard Boneu; Georges Houin; Francesco Gianese
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

6.  Anti-Coagulant and Anti-Thrombotic Properties of Blacklip Abalone (Haliotis rubra): In Vitro and Animal Studies.

Authors:  Hafiz Ansar Rasul Suleria; Paul P Masci; Kong-Nan Zhao; Rama Addepalli; Wei Chen; Simone A Osborne; Glenda C Gobe
Journal:  Mar Drugs       Date:  2017-08-04       Impact factor: 5.118

7.  In vitro Anti-Thrombotic Activity of Extracts from Blacklip Abalone (Haliotis rubra) Processing Waste.

Authors:  Hafiz Ansar Rasul Suleria; Barney M Hines; Rama Addepalli; Wei Chen; Paul Masci; Glenda Gobe; Simone A Osborne
Journal:  Mar Drugs       Date:  2016-12-31       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.